| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_72549d8730c04d55066958665341552d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S436-823
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J2220-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J2220-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-811 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-3071
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-3274
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-28004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-3257
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M1-3679
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-3217
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-103
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-3092
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-3085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-3204
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-3246
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-3248
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-3219 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M1-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B01J20-32 |
| filingDate |
1988-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1989-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_481608d47ea75048519175c8ec5b32b4 |
| publicationDate |
1989-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-4863869-A |
| titleOfInvention |
Anti-human IGM immunoadsorbent and process for producing said immunoadsorbent |
| abstract |
An immunoadsorbent material for removing IgM and IgM-complexes from biological fluids is prepared by covalently binding anti-IgM antibodies to a solid-phase silica matrix. It has been found that reacting hydroxy-derivatized silica in the presence of cyanogen bromide with the anti-IgM antibodies provides a particularly stable, high-capacity immunoadsorbent. The immunoadsorbent material may be employed in a column for therapeutic treatment of various disorders, such as primary biliary cirrhosis. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8603486-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005113299-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5858359-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7425331-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5948894-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7807170-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9370552-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011064762-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9316729-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007129285-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012301908-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8168189-B2 |
| priorityDate |
1986-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |